Vancouver-based Acuitas Therapeutics (www.acuitastx.com) partners with pharmaceutical and biotechnology companies, as well as non-governmental organizations and academic institutes, to advance nucleic acid therapeutics into clinical development and commercialization. Acuitas’ lipid nanoparticle (LNP) technology is clinically validated, enabling Alnylam Pharmaceuticals’ ONPATTRO® for the treatment of people with a rare genetic and otherwise fatal disorder known as transthyretin amyloidosis and the Pfizer-BioNTech COVID-19 vaccine, COMIRNATY®, which has protected billions of people in more than 180 countries. Acuitas has also helped to enable the first human proof-of-concept for genome base editing to treat a serious genetic disease. The company is currently focused on further innovations to its LNP carriers to advance the development of novel gene therapies, such as epigenetic medicines, to modulate gene expression without genetic editing to treat a range of diseases, including cancer. In addition, Acuitas works with partners on the development of improved vaccines – such as multi-valent vaccines to prevent a range of infectious diseases (including malaria, HIV/AIDS and tuberculosis) – and on novel therapeutic vaccines against cancer, including personalized cancer vaccines.